China Starch adds 1.55 million-share buyback; 29.55 million shares repurchased since May mandate

Bulletin Express06-04

China Starch Holdings Limited disclosed on 4 June 2026 that it repurchased 1.55 million ordinary shares on the Hong Kong Stock Exchange at HKD 0.167–0.168 per share, spending HKD 0.26 million. All shares will be cancelled.

Including this latest transaction, the company has bought back 29.55 million shares since the current 10% repurchase mandate was approved on 12 May 2026, equivalent to 0.50% of the 5.96 billion shares then in issue. The mandate still allows for the repurchase of up to 596.45 million shares, leaving a remaining capacity of about 566.90 million shares.

From 24 March to 4 June 2026, China Starch executed 30 on-market buybacks totalling 53.45 million shares that are pending cancellation. The volume-weighted average repurchase price across these trades is approximately HKD 0.18 per share, representing an aggregate outlay of roughly HKD 9.49 million. The largest single-day purchase in the period was 3.70 million shares on 27 April at HKD 0.1806 each.

Following the repurchases, the company’s issued share capital remains at 5.96 billion shares, as the bought-back shares have not yet been cancelled. In line with Main Board Rule 10.06, China Starch is subject to a moratorium on issuing new shares or disposing of treasury shares until 4 July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment